$SCLX
Scilex Holding Co Stock $sclx

$sclx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023006493 Filed on March 07, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$10.58M	$11.92M	$38.03M
YoY Change
Cost Of Revenue	$3.591M	$4.513M	$10.80M
YoY Change	213.9%	315.94%	197.11%
Gross Profit	$6.991M	$7.406M	$27.24M
YoY Change	-711.1%	3.18%	-849.5%
Gross Profit Margin	66.07%	62.14%	71.61%
Selling, General & Admin	$28.70M	$23.52M	$64.90M
YoY Change	163.12%	62.35%	28.3%
% of Gross Profit	410.54%	317.63%	238.26%
Research & Development	$2.736M	$2.597M	$9.054M
YoY Change	3.99%	19.68%	-1.6%
% of Gross Profit	39.14%	35.07%	33.24%
Depreciation & Amortization	$1.037M	$1.035M	$3.961M
YoY Change	9.85%	-72.61%	4.82%
% of Gross Profit	14.83%	13.98%	14.54%
Operating Expenses	$31.44M	$27.15M	$73.95M
YoY Change	9711.19%	6953.73%	7254.45%
Operating Profit	-$25.50M	-$19.74M	-$50.60M
YoY Change	189.58%	-390.6%	41.19%
Interest Expense	-$5.272M	$1.897M	$9.604M
YoY Change	95580.58%	210677.78%	33120.34%
% of Operating Profit
Other Income/Expense, Net	-$5.272M		$27.27M
YoY Change	997.65%		1423.48%
Pretax Income	-$30.75M	-$17.84M	-$23.36M
YoY Change	3713.48%	-1675.36%	-3081.72%
Income Tax	$8.000K	$40.00K	$4.000K
% Of Pretax Income
Net Earnings	-$30.75M	-$17.88M	-$23.36M
YoY Change	3714.46%	-1678.9%	-3082.23%
Net Earnings / Revenue	-290.62%	-150.05%	-61.43%
Basic Earnings Per Share	-$0.22		-$0.17
Diluted Earnings Per Share	-$0.22	-$0.13	-$0.17
COMMON SHARES
Basic Shares Outstanding	145.8M	13.18M shares	134.2K
Diluted Shares Outstanding	141.7M		134.2K

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.069M	$2.184M	$2.184M
YoY Change	3877.56%	329.99%	329.99%
Cash & Equivalents	$5.100M	$2.184M	$2.184M
Short-Term Investments
Other Short-Term Assets	$4.516M	$4.810M	$4.810M
YoY Change	1037.82%	105847.14%	105847.14%
Inventory	$2.275M	$1.378M	$1.378M
Prepaid Expenses
Receivables	$19.24M	$21.24M	$21.24M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$31.10M	$29.61M	$29.61M
YoY Change	5832.03%	5677.66%	5677.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$762.0K	$772.0K	$1.903M
YoY Change		-4.1%	-9.72%
Goodwill	$13.50M	$13.50M
YoY Change		0.0%
Intangibles	$39.56M	$40.59M
YoY Change		4.61%
Long-Term Investments
YoY Change
Other Assets	$153.0K	$944.0K	$944.0K
YoY Change	-99.89%	-99.32%	-99.32%
Total Long-Term Assets	$54.95M	$56.92M	$56.92M
YoY Change	-60.88%	-59.17%	-59.17%
TOTAL ASSETS
Total Short-Term Assets	$31.10M	$29.61M	$29.61M
Total Long-Term Assets	$54.95M	$56.92M	$56.92M
Total Assets	$86.05M	$86.53M	$86.53M
YoY Change	-38.96%	-38.16%	-38.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.817M	$8.450M	$8.450M
YoY Change	23843.9%	3948.87%	3948.87%
Accrued Expenses	$44.79M	$36.13M	$36.13M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$9.600M	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$64.60M	$44.84M	$44.84M
YoY Change	157465.85%	21385.93%	21386.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$168.0K	$163.0K	$5.446M
YoY Change	-98.48%	2265.06%	-39.7%
Total Long-Term Liabilities	$168.0K	$163.0K	$5.446M
YoY Change	-98.48%	2265.06%	-39.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.60M	$44.84M	$44.84M
Total Long-Term Liabilities	$168.0K	$163.0K	$5.446M
Total Liabilities	$74.98M	$50.29M	$50.29M
YoY Change	575.73%	444.23%	444.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$406.7M	-$375.9M
YoY Change		4221.96%
Common Stock	$15.00K	$14.00K
YoY Change		3957.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.08M	$36.24M	$36.24M
YoY Change
Total Liabilities & Shareholders Equity	$86.05M	$86.53M	$86.53M
YoY Change	-38.96%	-38.16%	-38.16%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$30.75M	-$17.88M	-$23.36M
YoY Change	3714.46%	-1678.9%	-3082.23%
Depreciation, Depletion And Amortization	$1.037M	$1.035M	$3.961M
YoY Change	9.85%	-72.61%	4.82%
Cash From Operating Activities	-$7.744M	-$725.0K	-$21.26M
YoY Change	779.52%	573.04%	2552.84%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$7.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$2.067M
YoY Change	-100.0%		-98.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.63M	426.0K	21.17M
YoY Change	592.44%	-14.8%	-84.95%
NET CHANGE
Cash From Operating Activities	-7.744M	-725.0K	-21.26M
Cash From Investing Activities	0.000	0.000	-2.067M
Cash From Financing Activities	10.63M	426.0K	21.17M
Net Change In Cash	2.885M	-299.0K	-2.154M
YoY Change	-858.25%	-176.22%	-551.18%
FREE CASH FLOW
Cash From Operating Activities	-$7.744M	-$725.0K	-$21.26M
Capital Expenditures		$0.00	$7.000K
Free Cash Flow		-$725.0K	-$21.27M
YoY Change		573.04%	2553.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	sclx	Accrual For Transaction Costs Related To The Business Combination AccrualForTransactionCostsRelatedToTheBusinessCombination
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	sclx	Accrual For Transaction Costs Related To The Business Combination AccrualForTransactionCostsRelatedToTheBusinessCombination
CY2021	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento
CY2021	sclx	Other Long Term Liabilities OtherLongTermLiabilities
CY2021Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2020	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001820190
CY2020	sclx	Other Long Term Liabilities OtherLongTermLiabilities
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#DerivativeLiabilitiesNoncurrent
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39852
CY2022	dei	Entity Registrant Name EntityRegistrantName	Scilex Holding Company
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	92-1062542
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	960 San Antonio Road
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94303
CY2022	dei	City Area Code CityAreaCode	(650
CY2022	dei	Local Phone Number LocalPhoneNumber	516-4310
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	SCLX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	99400000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	145800574
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4338000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21236000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14268000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1378000
CY2021Q4	us-gaap	Inventory Net InventoryNet	2562000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4810000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1835000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	29608000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	23003000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	805000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1131000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1303000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40591000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	38802000
CY2022Q4	us-gaap	Goodwill Goodwill	13481000
CY2021Q4	us-gaap	Goodwill Goodwill	13481000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	319000
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	944000
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	538000
CY2022Q4	us-gaap	Assets Assets	86527000
CY2021Q4	us-gaap	Assets Assets	77932000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8450000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4284000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1354000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3733000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30893000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7362000
CY2022Q4	sclx	Accrued Expenses AccruedExpenses	3136000
CY2021Q4	sclx	Accrued Expenses AccruedExpenses	3259000
CY2022Q4	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	264000
CY2021Q4	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	0
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	37950000
CY2022Q4	sclx	Related Party Payable RelatedPartyPayable	0
CY2021Q4	sclx	Related Party Payable RelatedPartyPayable	92724000
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19608000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	500000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44842000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	169420000
CY2022Q4	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	3387000
CY2021Q4	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	0
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	72037000
CY2022Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	23503000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1231000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	35700000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	665000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1148000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Liabilities Liabilities	50288000
CY2021Q4	us-gaap	Liabilities Liabilities	301808000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	45000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29057097
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29057097
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141348856
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141348856
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132858484
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	132858484
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412136000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	128661000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375914000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-352550000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36239000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-223876000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86527000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77932000
CY2022	us-gaap	Revenues Revenues	38034000
CY2021	us-gaap	Revenues Revenues	31317000
CY2020	us-gaap	Revenues Revenues	23560000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	10797000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3634000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	2149000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9054000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9201000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9961000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64895000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50582000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42970000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3922000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3738000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3738000
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	88668000
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	67155000
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	58818000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-50634000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-35838000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-35258000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8310000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	800000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12463000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2021	sclx	Notes Principal Increase NotesPrincipalIncrease	-28000000
CY2020	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2022	us-gaap	Interest Expense InterestExpense	9604000
CY2021	us-gaap	Interest Expense InterestExpense	11764000
CY2020	us-gaap	Interest Expense InterestExpense	13116000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-66000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10664000
CY2022	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2021	sclx	Notes Principal Increase NotesPrincipalIncrease	-28000000
CY2020	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2022	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	21190000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-54000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27274000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-52581000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12314000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23360000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88419000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47572000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-47519000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134226
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134226
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132858
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132858
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132891
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132891
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-90029000
CY2019	sclx	Recapitalization Due To The Business Combination Value RecapitalizationDueToTheBusinessCombinationValue	20000
CY2019	sclx	Effect Of Business Combination In Value EffectOfBusinessCombinationInValue	-90009000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5395000
CY2020	us-gaap	Profit Loss ProfitLoss	-47519000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-141683000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5822000
CY2021	sclx	Adjustment To Shares Issued In Semnur Acquisition Value AdjustmentToSharesIssuedInSemnurAcquisitionValue	409000
CY2021	us-gaap	Profit Loss ProfitLoss	-88424000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-223876000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000
CY2022	sclx	Adjustment To Additional Paid In Capital License Transfer Net Of Discount Value AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue	-4127000
CY2022	sclx	Adjustmenttoadditionalpaidincapitaldiscountamortization Adjustmenttoadditionalpaidincapitaldiscountamortization	-35000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	289733000
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	8706000
CY2022	sclx	Shares Issued To Yorkville Pursuant To Yorkville Purchase Agreement SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement	1238000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5280000
CY2022	us-gaap	Profit Loss ProfitLoss	-23364000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36239000
CY2021	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	12487000
CY2020	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	10866000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12463000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5822000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5395000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8310000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-47519000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3961000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3779000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3777000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3142000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7909000
CY2022	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	492000
CY2021	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	372000
CY2020	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	825000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5280000
CY2022	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	2949000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	800000
CY2022	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	1697000
CY2021	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	0
CY2020	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	0
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6968000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1142000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	598000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1184000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1417000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2379000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2629000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1479000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1035000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-350000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2580000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2806000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3836000
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-4062000
CY2022	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-2379000
CY2021	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-21000
CY2020	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	1247000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-123000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	664000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1066000
CY2022	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	23531000
CY2021	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	-255000
CY2020	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	3117000
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-392000
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-80000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-604000
CY2022	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	30125000
CY2021	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	18210000
CY2020	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	5105000
CY2022	sclx	Other Long Term Liabilities OtherLongTermLiabilities	163000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21258000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28664000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31461000
CY2022	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	2060000
CY2021	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	0
CY2020	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2067000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000
CY2022	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	3375000
CY2021	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	0
CY2020	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	0
CY2021	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	0
CY2020	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	0
CY2022	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-84808000
CY2021	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-33387000
CY2020	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-58927000
CY2022	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	-18800000
CY2021	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	-48832000
CY2020	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	0
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	9857000
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	47832000
CY2020	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	11007000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	51900000
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	47850000
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	18400000
CY2022	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	62500000
CY2021	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	14700000
CY2020	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	10300000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21171000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28163000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19170000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2154000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-501000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50656000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4338000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4839000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55495000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4338000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4839000
CY2022	sclx	Related Party Debt Converted To Equity Pursuant To Debt Exchange Agreement RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement	289733000
CY2022	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	3650000
CY2021	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	0
CY2020	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	0
CY2022	sclx	Non Cash Consideration In Semnur Acquisition NonCashConsiderationInSemnurAcquisition	0
CY2021	sclx	Non Cash Consideration In Semnur Acquisition NonCashConsiderationInSemnurAcquisition	409000
CY2020	sclx	Non Cash Consideration In Semnur Acquisition NonCashConsiderationInSemnurAcquisition	0
CY2022	sclx	Other Loan Forgiveness OtherLoanForgiveness	0
CY2021	sclx	Other Loan Forgiveness OtherLoanForgiveness	1536000
CY2020	sclx	Other Loan Forgiveness OtherLoanForgiveness	0
CY2022	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	4162000
CY2021	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	0
CY2020	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	0
CY2022	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	30400000
CY2022	sclx	Acquisition Of Right Of Use Asset AcquisitionOfRightOfUseAsset	320000
CY2022	sclx	Private Placement Warrant Liability Acquired PrivatePlacementWarrantLiabilityAcquired	2545000
CY2022	sclx	Forfeiture Of Private Warrants ForfeitureOfPrivateWarrants	1696000
CY2021	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	0
CY2020	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	0
CY2022	sclx	Change In Valuation Inputs Or Other Assumptions ChangeInValuationInputsOrOtherAssumptions	-38710000
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1231000
CY2021	sclx	Acquisition Of Right Of Use Asset AcquisitionOfRightOfUseAsset	0
CY2020	sclx	Acquisition Of Right Of Use Asset AcquisitionOfRightOfUseAsset	0
CY2022	sclx	Issuance Of Shares To Yorkville Pursuant To Yorkville Purchase Agreement IssuanceOfSharesToYorkvillePursuantToYorkvillePurchaseAgreement	1238000
CY2022	sclx	Non Cash Distribution To Sorrento NonCashDistributionToSorrento	0
CY2021	sclx	Non Cash Distribution To Sorrento NonCashDistributionToSorrento	0
CY2020	sclx	Non Cash Distribution To Sorrento NonCashDistributionToSorrento	9600000
CY2022	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2021	sclx	Notes Principal Increase NotesPrincipalIncrease	-28000000
CY2020	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2022	sclx	Accrual For Transaction Costs Related To The Business Combination AccrualForTransactionCostsRelatedToTheBusinessCombination	1372000
CY2022	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento	5148000
CY2022Q4	sclx	Transaction Costs Amount TransactionCostsAmount	3400000
CY2022	sclx	Common Stock Exchange Ratio Description CommonStockExchangeRatioDescription	as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16939436
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p>
CY2022Q4	sclx	Equity Value EquityValue	3.99
CY2022Q2	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.215
CY2022Q4	sclx	Derivative Warrant Liability Private Warrants DerivativeWarrantLiabilityPrivateWarrants	1200000
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	33400000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Prior to April 2, 2022, sales to the Company's sole distributor represented </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of net revenue. On April 2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The distributor continued to provide traditional third-party logistics functions for the Company. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company had four customers during the year ended December 31, 2022, which individually generated 10% or more of the Company’s total revenue. These customers accounted for </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">83</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of the Company’s revenue for the year ended December 31, 2022, individually ranging between </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. As of December 31, 2022, these customers represented </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> of the Company’s outstanding accounts receivable, individually ranging between </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. Additionally, during the fiscal years ended December 31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December 31, 2022, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2020	sclx	Loan Derivative Liability LoanDerivativeLiability	2800000
CY2020	sclx	Re Measurement Of Fair Value ReMeasurementOfFairValue	-800000
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	35400000
CY2021	sclx	Re Measurement Of Fair Value ReMeasurementOfFairValue	300000
CY2022Q4	sclx	Working Capital WorkingCapital	15200000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2200000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-50600000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	21300000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375900000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2184000
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1231000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1394000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4338000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4338000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	35700000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	35700000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8300000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	800000
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	30400000
CY2022Q2	sclx	Risk Adjusted Net Sales Forecast RiskAdjustedNetSalesForecast	0.061
CY2022Q4	sclx	Equity Value EquityValue	9.01
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	35700000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M9D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.350
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.100
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0394
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0391
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022	sclx	Call Option Value CallOptionValue	0.30
CY2022Q4	sclx	Call Option Value CallOptionValue	0.62
CY2022	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	3000000.0
CY2022Q4	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.100
CY2022Q4	sclx	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	939000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	932000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	167000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	127000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	805000
CY2022	us-gaap	Depreciation Depreciation	40000
CY2021	us-gaap	Depreciation Depreciation	39000
CY2020	us-gaap	Depreciation Depreciation	40000
CY2022Q4	us-gaap	Goodwill Goodwill	13500000
CY2021Q4	us-gaap	Goodwill Goodwill	13500000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60781000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-20190000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40591000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	55070000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-16268000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38802000
CY2022Q4	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y4M24D
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3700000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3700000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	4106000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	4031000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	4006000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	20436000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	4006000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	4006000
CY2022Q4	sclx	Estimated Future Amortization Expense Related To Intangible Assets EstimatedFutureAmortizationExpenseRelatedToIntangibleAssets	40591000
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	133997000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	30597000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2228000
CY2021Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	101172000
CY2021Q4	us-gaap	Debt Current DebtCurrent	29135000
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	72037000
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	115400000
CY2022	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	106000000.0
CY2021	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	45900000
CY2020	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	69800000
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3100000
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	7900000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10700000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28600000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12500000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141348856
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	132858484
CY2022Q4	us-gaap	Share Price SharePrice	18.00
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6899988
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17114000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.59
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2183000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4172000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.72
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	38000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.34
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	502000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.40
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20746000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.63
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2172000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1778000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.01
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18968000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	915000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	202000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1827000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16939000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38942000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	14487000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.70
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000
CY2022Q4	sclx	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	665000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	469000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	623000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	904000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	746000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	654000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	320000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.122
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	872000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	703000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1575000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	165000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1410000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2296000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-53000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-53000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10396000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12981000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3970000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1851000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2472000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-130000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12247000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15453000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4100000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1347000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	31000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	93000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10900000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15422000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4007000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48984000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39714000
CY2022Q4	sclx	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	15272000
CY2021Q4	sclx	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	12205000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2014000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1630000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1630000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1602000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3233000
CY2022Q4	sclx	Deferred Tax Assets Accrued Expense And Reserves DeferredTaxAssetsAccruedExpenseAndReserves	568000
CY2021Q4	sclx	Deferred Tax Assets Accrued Expense And Reserves DeferredTaxAssetsAccruedExpenseAndReserves	1517000
CY2022Q4	sclx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	315000
CY2021Q4	sclx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	404000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	77000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	236000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70462000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58939000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67543000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56643000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2919000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2666000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1975000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	253000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2919000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2296000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4905000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19150000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9408000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10900000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15422000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4007000
CY2022	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	-9293000
CY2021	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	8954000
CY2020	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	-806000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2469000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	224000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	166000
CY2022	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	992000
CY2021	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	75000
CY2020	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	63000
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-713000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-3968000
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	6955000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-174000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2545000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1164000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	101000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	728000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	993000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	235000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67500000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2000000.0
CY2022	sclx	Tax Credit Carry Forwards Expiration Year TaxCreditCarryForwardsExpirationYear	2035
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	406000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	385000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	4000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	25000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	406000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-47519000
CY2022	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0
CY2021	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0
CY2020	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23364000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-88424000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-47519000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134226
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132858
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132891
CY2022	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2021	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2020	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2022	us-gaap	Dilutive Securities DilutiveSecurities	134226000
CY2021	us-gaap	Dilutive Securities DilutiveSecurities	132858000
CY2020	us-gaap	Dilutive Securities DilutiveSecurities	132891000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36

Files In Submission

Name	View Source	Status
R37.htm	Edgar Link	pending
0000950170-23-006493-index-headers.html	Edgar Link	pending
0000950170-23-006493-index.html	Edgar Link	pending
0000950170-23-006493.txt	Edgar Link	pending
0000950170-23-006493-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img248422670_0.jpg	Edgar Link	pending
img248422670_1.jpg	Edgar Link	pending
img248422670_10.jpg	Edgar Link	pending
img248422670_11.jpg	Edgar Link	pending
img248422670_12.jpg	Edgar Link	pending
img248422670_13.jpg	Edgar Link	pending
img248422670_14.jpg	Edgar Link	pending
img248422670_15.jpg	Edgar Link	pending
img248422670_2.jpg	Edgar Link	pending
img248422670_3.jpg	Edgar Link	pending
img248422670_4.jpg	Edgar Link	pending
img248422670_5.jpg	Edgar Link	pending
img248422670_6.jpg	Edgar Link	pending
img248422670_7.jpg	Edgar Link	pending
img248422670_8.jpg	Edgar Link	pending
img248422670_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
sclx-20221231.htm	Edgar Link	pending
sclx-20221231.xsd	Edgar Link	pending
sclx-ex23_1.htm	Edgar Link	pending
sclx-ex31_1.htm	Edgar Link	pending
sclx-ex31_2.htm	Edgar Link	pending
sclx-ex32_1.htm	Edgar Link	pending
sclx-ex4_2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sclx-20221231_cal.xml	Edgar Link	unprocessable
sclx-20221231_def.xml	Edgar Link	unprocessable
sclx-20221231_lab.xml	Edgar Link	unprocessable
sclx-20221231_pre.xml	Edgar Link	unprocessable
sclx-20221231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCLX
Scilex Holding Co Stock $sclx

2023 Q1 Form 10-K Financial Statement

#000095017023006493 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX Scilex Holding Co Stock $sclx

2023 Q1 Form 10-K Financial Statement

#000095017023006493 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX
Scilex Holding Co Stock $sclx